DPP-4 Inhibition, Incretins and Islet Function

Inclusion Criteria: * • Caucasian men or women with type 2 diabetes diagnosed according to ICD10 at time of inclusion * Ongoing treatment with life style adjustment including diet and exercise regimen together with metformin as oral antidiabetic . Metformin therapy should be stable the last three months * Age 40-75 years * HbA1c 52-80 mmol/mol (inclusive) * BMI: 20-40 kg/m2 * Written informed consent has been given * Capability and willingness to participate in the whole study Exclusion Criteria: * • Liver disease (K70-77 in ICD10) or liver enzymes three times above upper reference range * Diabetic nephropathy (GFR \< 30 mL/min/1.73 m2 or albuminuria) or other causes of renal disease * Proliferative diabetic retinopathy * Treatment with any glucose-lowering medication except metformin * Previous myocardial infarction, coronary heart disease or instable angina pectoris in the last 6 months. * Symptomatic heart failure (NYHA class II-III) * Previous surgery on the gastrointestinal tract * Larger surgical intervention during the last 12 weeks * Female subject who are pregnant or breast feeding * Women of child bearing potential not using a highly effective method of birth control * Treatment with oral steroids, thiazide diuretics, digoxin or growth hormone * Hypersensitivity to the active substances of to any of the excipients * Participation in another study the last 4 weeks * Smoker * Paracetamol intolerance